ClinicalTrials.gg
CompletedNCT02775916Updated Jan 5, 2021Results posted

Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

A Phase 2 interventional study of CDZ173 and Placebo in Primary Sjögren's Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This Study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173 in patients with primary Sjögren's syndrome.

Read the detailed description

This study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary therapeutic efficacy of oral administrations of CDZ173, a selective PI3K delta inhibitor, for 12 weeks, in patients with primary Sjögren's syndrome. Data from this study will provide the basis for further development of the compound for the treatment of primary Sjögren's syndrome.

02

Conditions studied

  • Primary Sjögren's Syndrome
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary Sjögren's syndrome (pSS)
  • ESSDAI score ≥ 6 at screening visit

Exclusion criteria

Exclusion Criteria:

  • Secondary Sjögren's syndrome

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    CDZ173

    Capsule

    Drug: CDZ173

  • Placebo comparator
    Placebo

    Capsule matching Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Primary Sjögren's Syndrome With Adverse Events and Death up to Day 85

    Safety and tolerability of CDZ173 in patients with primary Sjögren's syndrome up to End of Treatment Day 85

    Time frame: up to Day 85

  2. Change From Baseline in the EULAR Sjögren's Syndrome Patient Reported Intensity (ESSPRI) After 12 Weeks of Treatment Day 85

    The ESSPRI is an established disease outcome measure for Sjögren's syndrome. The ESSPRI is a patient-reported, subjective symptom index for primary Sjögren's syndrome developed by the EULAR consortium. It consists of three questions covering the cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain (articular and/or muscular). Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10.

    Time frame: Baseline and 12 weeks (Day 85)

Secondary outcomes

  1. Change From Baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) After 12 Weeks of Treatment Day 85

    The ESSDAI is an established disease outcome measure for Sjögren's syndrome. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score. A reduction from baseline (i.e., a negative change from baseline) in the ESSDAI score is indicative of improvement in a patient.). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. An overall score is then calculated as the sum of all individual weighted domain scores. Overall score is calculated as sum of all individual weighted domain scores (ranges from 0 (best) to 123 (worst activity).

    Time frame: Baseline and 12 weeks (Day 85)

  2. Change From Baseline in the Short Form (36) Health Survey (SF-36) After 12 Weeks of Treatment Day 85

    The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.

    Time frame: Baseline and 12 weeks (Day 85)

  3. Change in Baseline in Multidimensional Fatigue Inventory (MFI) After 12 Weeks of Treatment (Day 85)

    The Multidimensional Fatigue Inventory (MFI) is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a possible range from 4-20. The reported total score has a range from 20-100. The reported total score has a range from 20-100, higher scores are associated with greater fatigue.

    Time frame: Baseline and 12 weeks (Day 85)

  4. Change From Baseline in Physician Global Assessment of the Patient's Overall Disease Activity (Physician VAS) After 12 Weeks of Treatment Day 85

    A reduction from baseline (i.e., a negative change from baseline) in physician global VAS assessment score indicates improvement in patients. The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).

    Time frame: Baseline and 12 weeks (Day 85)

  5. Change From Baseline in Patient's Global Assessment of Their Disease Activity (VAS) After 12 Weeks of Treatment Day 85

    A reduction from baseline (or, a negative change from baseline) in patient global VAS assessment score indicates improvement in patients. The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).

    Time frame: Baseline and 12 weeks

07

Results

Posted Oct 18, 2019

Participant flow

Participant flow — Overall Study
MilestoneCDZ173Placebo
Started2010
Completed1710
Not completed30
Withdrew: Adverse event10
Withdrew: Subject/guardian decision20

Outcome measures

PrimaryNumber of Participants With Primary Sjögren's Syndrome With Adverse Events and Death up to Day 85

Safety and tolerability of CDZ173 in patients with primary Sjögren's syndrome up to End of Treatment Day 85

Time frame:
up to Day 85
Reported as:
Number · count of participants
Number of Participants With Primary Sjögren's Syndrome With Adverse Events and Death up to Day 85
count of participantsCDZ173Placebo
Participants with at least one AE208
Participants with at least one SAE10
Death00
PrimaryChange From Baseline in the EULAR Sjögren's Syndrome Patient Reported Intensity (ESSPRI) After 12 Weeks of Treatment Day 85

The ESSPRI is an established disease outcome measure for Sjögren's syndrome. The ESSPRI is a patient-reported, subjective symptom index for primary Sjögren's syndrome developed by the EULAR consortium. It consists of three questions covering the cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain (articular and/or muscular). Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and an overall score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10.

Time frame:
Baseline and 12 weeks (Day 85)
Reported as:
Mean · total score on scale
Change From Baseline in the EULAR Sjögren's Syndrome Patient Reported Intensity (ESSPRI) After 12 Weeks of Treatment Day 85
total score on scaleCDZ173Placebo
Change From Baseline in the EULAR Sjögren's Syndrome Patient Reported Intensity (ESSPRI) After 12 Weeks of Treatment Day 85-1.778 ± 2.4509-0.741 ± 1.3517
Statistical analysis
  • CDZ173 vs Placebo · Mean difference (net): -0.69 · 95% CI -3.343 to 1.937
SecondaryChange From Baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) After 12 Weeks of Treatment Day 85

The ESSDAI is an established disease outcome measure for Sjögren's syndrome. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score. A reduction from baseline (i.e., a negative change from baseline) in the ESSDAI score is indicative of improvement in a patient.). Each domain is assessed for activity level (i.e., no, low, moderate, high) and assigned a numerical score based on pre-determined weighting of each individual domain. An overall score is then calculated as the sum of all individual weighted domain scores. Overall score is calculated as sum of all individual weighted domain scores (ranges from 0 (best) to 123 (worst activity).

Time frame:
Baseline and 12 weeks (Day 85)
Reported as:
Least squares mean · total score on scale
Change From Baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) After 12 Weeks of Treatment Day 85
total score on scaleCDZ173Placebo
Change From Baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) After 12 Weeks of Treatment Day 85-2.82 ± 1.165-3.34 ± 1.168
Statistical analysis
  • CDZ173 vs Placebo · Mean difference (net): 0.51 · 95% CI -2.52 to 3.55
SecondaryChange From Baseline in the Short Form (36) Health Survey (SF-36) After 12 Weeks of Treatment Day 85

The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.

Time frame:
Baseline and 12 weeks (Day 85)
Reported as:
Least squares mean · total score on a scale
Change From Baseline in the Short Form (36) Health Survey (SF-36) After 12 Weeks of Treatment Day 85
total score on a scaleCDZ173Placebo
Physical Component Summary Score4.82 ± 2.2354.42 ± 2.425
Mental Component Summary Score5.43 ± 3.4151.10 ± 3.792
Statistical analysis
  • CDZ173 vs Placebo · Mean difference (net): 0.40 · 95% CI -6.08 to 6.89
  • CDZ173 vs Placebo · Mean difference (net): 4.33 · 95% CI -5.27 to 13.93
SecondaryChange in Baseline in Multidimensional Fatigue Inventory (MFI) After 12 Weeks of Treatment (Day 85)

The Multidimensional Fatigue Inventory (MFI) is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a possible range from 4-20. The reported total score has a range from 20-100. The reported total score has a range from 20-100, higher scores are associated with greater fatigue.

Time frame:
Baseline and 12 weeks (Day 85)
Reported as:
Least squares mean · total score on scale
Change in Baseline in Multidimensional Fatigue Inventory (MFI) After 12 Weeks of Treatment (Day 85)
total score on scaleCDZ173Placebo
Change in Baseline in Multidimensional Fatigue Inventory (MFI) After 12 Weeks of Treatment (Day 85)-8.80 ± 5.557-2.25 ± 5.774
Statistical analysis
  • CDZ173 vs Placebo · Mean difference (net): -6.55 · 95% CI -21.76 to 8.66
SecondaryChange From Baseline in Physician Global Assessment of the Patient's Overall Disease Activity (Physician VAS) After 12 Weeks of Treatment Day 85

A reduction from baseline (i.e., a negative change from baseline) in physician global VAS assessment score indicates improvement in patients. The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).

Time frame:
Baseline and 12 weeks (Day 85)
Reported as:
Least squares mean · total score on a scale
Change From Baseline in Physician Global Assessment of the Patient's Overall Disease Activity (Physician VAS) After 12 Weeks of Treatment Day 85
total score on a scaleCDZ173Placebo
Change From Baseline in Physician Global Assessment of the Patient's Overall Disease Activity (Physician VAS) After 12 Weeks of Treatment Day 85-10.06 ± 6.5840.91 ± 7.699
Statistical analysis
  • CDZ173 vs Placebo · Mean difference (net): -10.97 · 95% CI -30.94 to 9.00
SecondaryChange From Baseline in Patient's Global Assessment of Their Disease Activity (VAS) After 12 Weeks of Treatment Day 85

A reduction from baseline (or, a negative change from baseline) in patient global VAS assessment score indicates improvement in patients. The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · total score on a scale
Change From Baseline in Patient's Global Assessment of Their Disease Activity (VAS) After 12 Weeks of Treatment Day 85
total score on a scaleCDZ173Placebo
Change From Baseline in Patient's Global Assessment of Their Disease Activity (VAS) After 12 Weeks of Treatment Day 85-4.83 ± 7.2682.87 ± 8.412
Statistical analysis
  • CDZ173 vs Placebo · Mean difference (net): -7.69 · 95% CI -29.75 to 14.37

Adverse events

Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit (Day 113). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CDZ1730/20 (0%)1/20 (5%)19/20 (95%)
Placebo0/10 (0%)0/10 (0%)8/10 (80%)
Most frequent serious events
Most frequent serious events
EventCDZ173Placebo
RashSkin and subcutaneous tissue disorders1/200/10
Most frequent other events
Showing 10 of 35
Most frequent other events
EventCDZ173Placebo
RashSkin and subcutaneous tissue disorders10/201/10
Viral Upper Respiratory Tract InfectionInfections and infestations7/204/10
HeadacheNervous system disorders7/201/10
FlatulenceGastrointestinal disorders1/203/10
DiarrhoeaGastrointestinal disorders5/201/10
Upper Respiratory Tract InfectionInfections and infestations3/200/10
DyspnoeaRespiratory, thoracic and mediastinal disorders3/200/10
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders3/200/10
Dry EyeEye disorders1/201/10
Abdominal PainGastrointestinal disorders2/200/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)CDZ173PlaceboTotal
Mean48.7 ± 13.8544.7 ± 11.5847.3 ± 13.07
Sex: Female, Male
Sex: Female, Male(Participants)CDZ173PlaceboTotal
Female17926
Male314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CDZ173PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino201030
Unknown or Not Reported000
08

Study locations

2 sites
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in May 2017, 11 months.

Results were first posted in Oct 2019, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2016
First posted
May 18, 2016
StartActual
Jun 1, 2016
Primary completionActual
May 17, 2017
CompletionActual
May 17, 2017
Results first posted
Oct 18, 2019
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02775916
Responsible party
Sponsor
First posted
May 18, 2016
Start date
Jun 1, 2016
Primary completion
May 17, 2017
Completion
May 17, 2017
Results posted
Oct 18, 2019
Last update
Jan 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leniolisib

Start the discussion